CAS 1661854-97-2

Zipalertinib

CAS: 1661854-97-2

Formel: C₂₃H₂₀N₆O

Reinheit: 97%

Farbe und Form: Solid

Molekulargewicht: 396.4445

Ref: IN-DA01EO8V

N-[(8S)-4-Amino-6-Methyl-5-Quinolin-3-Yl-8,9-Dihydropyrimido[5,4-b]Indolizin-8-Yl]Prop-2-Enamide

CAS: 1661854-97-2

N-[(8S)-4-Amino-6-Methyl-5-Quinolin-3-Yl-8,9-Dihydropyrimido[5,4-b]Indolizin-8-Yl]Prop-2-Enamide

Reinheit: 97%

Molekulargewicht: 396.4g/mol

Ref: 54-OR1024053

TAS6417

CAS: 1661854-97-2

TAS6417

Reinheit: ≥98%

Molekulargewicht: 396.44g/mol

Ref: 54-BUP12830

TAS6417

CAS: 1661854-97-2

Zipalertinib (TAS6417, CLN-081) is a novel, highly potent, orally active covalent EGFR tyrosine kinase inhibitor.Cost-effective and quality-assured.

Formel: C₂₃H₂₀N₆O

Reinheit: 99.71%

Farbe und Form: Solid

Molekulargewicht: 396.44

Ref: TM-T16996

TAS 6417 hydrochloride

CAS: 1661854-97-2

TAS 6417 hydrochloride is a small-molecule inhibitor, which is synthesized via chemical processes in pharmaceutical research. It functions primarily as a potent and selective inhibitor of specific mutant forms of the epidermal growth factor receptor (EGFR). By targeting these EGFR mutations, TAS 6417 hydrochloride disrupts the signaling pathways that are crucial for the proliferation and survival of cancer cells.

Formel: C₂₃H₂₀N₆O·HCl

Reinheit: Min. 95%

Molekulargewicht: 432.91 g/mol

Ref: 3D-BT171643

TAS 6417

CAS: 1661854-97-2

Inhibits mutated EGFR with exon 20 insertion; anti-cancer agent

Formel: C₂₃H₂₀N₆O

Reinheit: Min. 95%

Molekulargewicht: 396.44 g/mol

Ref: 3D-FT166464